GBIM (GBIM) Stock Price & Analysis
GBIM (GBIM) rose 0.00% to USD 0 as of June 10, 2026 at 08:43 UTC, according to Nexqual real-time market data.
GBIM last closed at USD 0; the session ranged USD 0–0 on volume of 756 shares. Market capitalization is $575, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 08:43 UTC.
Key Statistics (as of June 10, 2026 at 08:43 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 756 shares |
| Market Cap | $575 |
| Exchange | PNK |
Technical Analysis (GBIM)
Nexqual's technical model rates GBIM "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 08:43 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (GBIM)
Wall Street analysts rate GBIM "None", per Nexqual as of June 10, 2026 at 08:43 UTC.
| Consensus Rating | None |
|---|
Earnings (GBIM)
Source: Nexqual, June 10, 2026 at 08:43 UTC.
Financials & Fundamentals (GBIM)
| Total Revenue | $6.21M |
|---|---|
| Revenue Growth (YoY) | -20.60% |
| Gross Margin | +66.52% |
| Operating Margin | -91.46% |
| Profit Margin | -33.30% |
| ROE | -66.24% |
| Current Ratio | 2.28 |
| Total Cash | $8.69M |
| Total Debt | $0 |
| Free Cash Flow | $-1.65M |
Source: Nexqual, June 10, 2026 at 08:43 UTC.
Financial Health Score (GBIM)
Nexqual rates GBIM's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 08:43 UTC.
| Growth | Critical — Revenue -21% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $9M cash, no debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Critical — ROE -66%, ROA -10.3% |
Ownership (GBIM)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.02% |
| Shares Outstanding | 5.75M |
| Float | 4.37M |
| Short % of Float | +3.49% |
Source: Nexqual, June 10, 2026 at 08:43 UTC.
Leadership (GBIM)
GBIM is led by Donald Bellgrau, Scientific Founder & Chairman of The Scientific Advisory Board, per Nexqual as of June 10, 2026 at 08:43 UTC.
| Scientific Founder & Chairman of The Scientific Advisory Board | Donald Bellgrau |
|---|
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TLOG | TETRALOGIC PHARMACEUTICALS CORP | USD 0 | ▲ 0% |
| BSPM | Biostar Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| CAPN | Cayson Acquisition Corp | USD 11.03 | ▲ 0% |
| GLRI | GLORI ENERGY INC | USD 0 | ▲ 0% |
| CLRB | Cellectar Biosciences, Inc. | USD 2.36 | ▼ 8.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:43 UTC. This page is informational and not investment advice.